Compare Citius Pharmaceuticals Inc (CTXR) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Kohl's Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Kohl's Corporation trades at $20.41 (market cap $2.28B). The key difference: Kohl's Corporation is far larger — about 167.4× Citius Pharmaceuticals Inc's market cap, and Kohl's Corporation pays a 2.49% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Kohl's Corporation for 48 Days on average.
| CTXR | KSS | |
|---|---|---|
Market Cap | $13.62M | $2.28B |
Volume | 132,438 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $24.71 |
52-Week Low | $0.48 | $11.72 |
Typical Hold Time | 17 Days | 48 Days |
Enterprise Value | $3.79M | $7.88B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Kohl's (KSS) trades at $20.28, up 0.8% with a bullish technical signal despite overbought RSI readings. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and raised guidance signal operational improvement. However, revenue has declined for 18 consecutive quarters, presenting a challenging growth environment.
The investment case balances deep value against persistent sales declines. While low valuations and margin improvements support upside potential, sustained revenue weakness and competitive pressures remain key risks. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
